1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Lynparza/Recentin Combo Fails In Phase III PSR Ovarian Cancer

Disappointment For AstraZeneca

 
• By Alexandra Shimmings

Lynparza will weather the failure of the Phase III GY004 study, but VEGF inhibitor Recentin’s future looks even less certain; other studies of the combination continue.    

Ovarian cancer
Ovarian cancer is difficult to treat • Source: Shutterstock

There is no benefit in using a combination of AstraZeneca PLC’s investigational oral VEGF receptor tyrosine kinase inhibitor, Recentin (cedirinib), and AZ/Merck & Co. Inc.’s PARP inhibitor Lynparza (olaparib) over platinum-based chemotherapy to treat patients with platinum-sensitive relapsed ovarian cancer, top-line data from the Phase III GY004 study show. The results are another disappointment for Recentin, but they should do little to dent Lynparza’s dominance of the ovarian cancer PARP inhibitor market.

The GY004 trial, led by NRG Oncology and sponsored by the US National Cancer Institute (NCI), saw no improvement in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

 
• By Sushmita Panda

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

More from R&D

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

 
• By Sushmita Panda

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

NewAmsterdam’s CETP Inhibitor Improves Alzheimer’s Biomarkers

 
• By Mandy Jackson

Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.